BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary Angioedema

By: via Benzinga
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the initiation of a Phase 1 clinical trial to evaluate the safety, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.